Plain-English translation of NCT07138144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether dolutegravir/lamivudine (a two-drug combination) works just as well as the standard three-drug HIV regimens that many people currently take. If you're already taking HIV medication and your virus is well-controlled, this study asks whether you could switch to this simpler medication schedule and still stay healthy.
Many people living with HIV take three-drug regimens that can cause unwanted side effects like weight gain, changes in cholesterol and blood sugar, and heart or kidney problems—especially in certain populations. This medication is designed to work just as well while being gentler on your body and easier to manage.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll either stay on your current three-drug routine or switch to the two-drug medication. You'll visit the study clinic at 24 weeks and 48 weeks, where they'll check your blood work, measure things like blood pressure and waist size, and ask about any side effects. The study team will make sure your HIV stays under control throughout.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
Mexico